Investor Relations
Corporate Profile
Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC(R) protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Price
Change
Volume
News Releases
Events
Nov 27, 2018 at 8:00 AM EST
Jun 12, 2019 at 3:20 PM PDT
Jun 25, 2019 at 2:00 PM EDT
Presentations
December 2, 2019
October 23, 2019